The “stacked” pipeline of biotech specialty crops and regulatory/market barriers to coexistence

dc.contributor.author	Redick, Thomas P
dc.date.accessioned	2017-06-08T17:34:44Z
dc.date.available	2017-06-08T17:34:44Z
dc.date.issued	2013
dc.description.abstract	Biotech specialty crops face a number of potential barriers. Regulatory uncertainty over new plant-breeding methods and costly overseas approvals could complicate plans for commercialization. Stacking a generic crop aids innovators in the marketplace, but generic crops may need the regulatory data held by patent holders to achieve regulatory approval. Sustainability standards may arbitrarily deny use of biotechnology. Any innovator heading into this sector will need to be aware of all the potential threats awaiting these exciting opportunities in genetic engineering of biotech crops.
dc.identifier.uri	https://hdl.handle.net/1813/51413
dc.language.iso	en_US
dc.publisher	NABC
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International	*
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	Agricultural biotechnology
dc.subject	specialty crops
dc.subject	transgenic papaya
dc.subject	stakeholders
dc.subject	genetic engineering
dc.subject	GE
dc.subject	GMO
dc.subject	regulation
dc.subject	food safety
dc.subject	USDA
dc.subject	novel traits
dc.subject	premarket approval
dc.subject	intellectual property
dc.subject	patents
dc.subject	human health impacts
dc.subject	synthetic genomics
dc.title	The “stacked” pipeline of biotech specialty crops and regulatory/market barriers to coexistence
dc.type	book chapter

Files

Now showing 1 - 1 of 1